FAQ: Quantum BioPharma's Private Placement of Class A Multiple Voting Shares
Summary
Quantum BioPharma announced a non-brokered private placement of up to 30 Class A multiple voting shares at $25 per share for gross proceeds of up to $750, which will restore voting rights to nearly their original 2018 level and provide working capital.
What is the main announcement in this content?
Quantum BioPharma announced a non-brokered private placement of up to 30 Class A multiple voting shares at $25 per share for gross proceeds of up to $750.
Why is this private placement significant for Quantum BioPharma?
The offering will increase voting rights attached to the Class A shares to 75.27%, restoring them to nearly their original level when the company went public in 2018, and provides working capital for the company.
Who is expected to subscribe to this private placement?
The offering is expected to be fully subscribed by entities controlled by Zeeshan Saeed and Anthony Durkacz.
When was this private placement approved?
The offering was approved by shareholders on September 26, 2025.
How will the proceeds from this offering be used?
Proceeds will be used for general working capital purposes.
What does Quantum BioPharma focus on as a biopharmaceutical company?
Quantum BioPharma is dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders.
What is Quantum BioPharma’s lead compound and what does it treat?
Through its subsidiary Lucid Psycheceuticals, Quantum BioPharma is developing Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
What is Quantum BioPharma’s relationship with Unbuzzd Wellness Inc.?
Quantum BioPharma retains ownership of 20.11% of Unbuzzd Wellness Inc. and receives royalty payments of 7% of sales from unbuzzd™ until payments total $250 million, after which the royalty drops to 3% in perpetuity.
Where can investors find more information about Quantum BioPharma?
The latest news and updates relating to QNTM are available in the company’s newsroom at https://www.investorbrandnetwork.com/clients/quantum-biopharma-ltd/
What other business activities does Quantum BioPharma engage in?
Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 270137